Position of the Transparency Council – Tavneos (avacopan)

At its meeting on 25 November 2024, the Transparency Council adopted position No. 132/2024 on the evaluation of the drug Tavneos (avacopan) in the framework of the drug programme B.75. “Treatment of patients with active granulomatosis with vasculitis (GPA) or microscopic vasculitis (MPA) (ICD-10: M31.3, M31.8)”

Publication of the position >>